JP5346820B2 - Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体 - Google Patents
Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体 Download PDFInfo
- Publication number
- JP5346820B2 JP5346820B2 JP2009553239A JP2009553239A JP5346820B2 JP 5346820 B2 JP5346820 B2 JP 5346820B2 JP 2009553239 A JP2009553239 A JP 2009553239A JP 2009553239 A JP2009553239 A JP 2009553239A JP 5346820 B2 JP5346820 B2 JP 5346820B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- subtype
- antibodies
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241001473385 H5N1 subtype Species 0.000 title claims abstract description 91
- 241000712461 unidentified influenza virus Species 0.000 title claims description 62
- 239000000427 antigen Substances 0.000 claims description 59
- 108091007433 antigens Proteins 0.000 claims description 59
- 102000036639 antigens Human genes 0.000 claims description 59
- 230000027455 binding Effects 0.000 claims description 58
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 54
- 101710154606 Hemagglutinin Proteins 0.000 claims description 46
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 46
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 46
- 101710176177 Protein A56 Proteins 0.000 claims description 46
- 230000003472 neutralizing effect Effects 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 36
- 239000000185 hemagglutinin Substances 0.000 claims description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 31
- 150000007523 nucleic acids Chemical class 0.000 claims description 31
- 239000012634 fragment Substances 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 25
- 102000039446 nucleic acids Human genes 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 20
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 238000003745 diagnosis Methods 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 241000712431 Influenza A virus Species 0.000 abstract description 7
- 241000700605 Viruses Species 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 35
- 238000000034 method Methods 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 32
- 239000008194 pharmaceutical composition Substances 0.000 description 23
- 210000003719 b-lymphocyte Anatomy 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 210000004072 lung Anatomy 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 241000282412 Homo Species 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 229940036185 synagis Drugs 0.000 description 9
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 206010022000 influenza Diseases 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 102000005348 Neuraminidase Human genes 0.000 description 6
- 108010006232 Neuraminidase Proteins 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 108010029566 avian influenza A virus hemagglutinin Proteins 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 206010064097 avian influenza Diseases 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940022353 herceptin Drugs 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- 208000002979 Influenza in Birds Diseases 0.000 description 4
- 230000009824 affinity maturation Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000006806 disease prevention Effects 0.000 description 4
- 231100000225 lethality Toxicity 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 4
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000252870 H3N2 subtype Species 0.000 description 3
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 3
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229960003752 oseltamivir Drugs 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 229960001028 zanamivir Drugs 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000252843 H5N2 subtype Species 0.000 description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 102000009438 IgE Receptors Human genes 0.000 description 2
- 108010073816 IgE Receptors Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 231100000645 Reed–Muench method Toxicity 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- -1 galactose sugars Chemical class 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229940048921 humira Drugs 0.000 description 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000002911 sialidase inhibitor Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000013595 supernatant sample Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940061367 tamiflu Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- 108010021470 Fc gamma receptor IIC Proteins 0.000 description 1
- 241000197306 H1N1 subtype Species 0.000 description 1
- 101710182312 High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 101710180643 Leishmanolysin Proteins 0.000 description 1
- 101710122625 Low affinity immunoglobulin gamma Fc region receptor II Proteins 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029206 Low affinity immunoglobulin gamma Fc region receptor II-c Human genes 0.000 description 1
- 101710177649 Low affinity immunoglobulin gamma Fc region receptor III Proteins 0.000 description 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- WPDOZYZAJKUVRZ-NRYSMURASA-N S-[(2R,3S,4S,6S)-6-[[(2R,3S,4S,5R,6R)-5-[(2S,4S,5S)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-4-hydroxy-6-[[(2S,5Z,9R)-9-hydroxy-12-(methoxycarbonylamino)-13-[2-(methyltrisulfanyl)ethylidene]-11-oxo-2-bicyclo[7.3.1]trideca-1(12),5-dien-3,7-diynyl]oxy]-2-methyloxan-3-yl]amino]oxy-4-hydroxy-2-methyloxan-3-yl] 4-[(2S,3R,4R,5S,6S)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5-iodo-2,3-dimethoxy-6-methylbenzenecarbothioate Chemical compound CCN([C@H]1CO[C@H](C[C@@H]1OC)O[C@@H]1[C@@H](O)[C@H](NO[C@H]2C[C@H](O)[C@H](SC(=O)c3c(C)c(I)c(O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)[C@H]4O)c(OC)c3OC)[C@@H](C)O2)[C@@H](C)O[C@H]1O[C@H]1C#C\C=C/C#C[C@]2(O)CC(=O)C(NC(=O)OC)=C1C2=CCSSSC)C(C)=O WPDOZYZAJKUVRZ-NRYSMURASA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000012452 Xenomouse strains Methods 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012514 monoclonal antibody product Substances 0.000 description 1
- 229960001521 motavizumab Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960002194 oseltamivir phosphate Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 108010052044 polyclonal B cell activator Proteins 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940061374 relenza Drugs 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002333 serotherapy Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89461207P | 2007-03-13 | 2007-03-13 | |
| US60/894,612 | 2007-03-13 | ||
| PCT/IB2008/001527 WO2008110937A2 (en) | 2007-03-13 | 2008-03-13 | Antibodies against h5n1 strains of influenza a virus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010521147A JP2010521147A (ja) | 2010-06-24 |
| JP2010521147A5 JP2010521147A5 (OSRAM) | 2011-05-06 |
| JP5346820B2 true JP5346820B2 (ja) | 2013-11-20 |
Family
ID=39760169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009553239A Expired - Fee Related JP5346820B2 (ja) | 2007-03-13 | 2008-03-13 | Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8124092B2 (OSRAM) |
| EP (1) | EP2125886A2 (OSRAM) |
| JP (1) | JP5346820B2 (OSRAM) |
| CN (1) | CN102046654A (OSRAM) |
| WO (1) | WO2008110937A2 (OSRAM) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2526720C (en) | 2003-05-22 | 2013-10-22 | Fraunhofer Usa, Inc. | Recombinant carrier molecule for expression, delivery and purification of target polypeptides |
| CA2616859C (en) | 2005-08-03 | 2015-04-14 | Fraunhofer Usa, Inc. | Compositions and methods for production of immunoglobulins |
| JP5346820B2 (ja) * | 2007-03-13 | 2013-11-20 | エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー | Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体 |
| US8404252B2 (en) | 2007-07-11 | 2013-03-26 | Fraunhofer Usa, Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
| CN102216327A (zh) * | 2008-07-25 | 2011-10-12 | 生物医学研究所 | 中和抗甲型流感病毒抗体及其用途 |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| WO2010037046A1 (en) | 2008-09-28 | 2010-04-01 | Fraunhofer Usa, Inc. | Humanized neuraminidase antibody and methods of use thereof |
| GB0818356D0 (en) * | 2008-10-07 | 2008-11-12 | Istituto Superiore Di Sanito | Antibodies |
| ES2525346T3 (es) | 2008-10-22 | 2014-12-22 | Institute For Research In Biomedicine | Métodos para producir anticuerpos a partir de células plasmáticas |
| WO2010130636A1 (en) | 2009-05-11 | 2010-11-18 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof |
| US8784819B2 (en) * | 2009-09-29 | 2014-07-22 | Ibio Inc. | Influenza hemagglutinin antibodies, compositions and related methods |
| AU2011289275A1 (en) * | 2010-08-12 | 2013-02-21 | Theraclone Sciences, Inc. | Anti-hemagglutinin antibody compositions and methods of use thereof |
| CN102775469B (zh) * | 2011-05-12 | 2018-02-09 | 厦门大学 | 甲型流感病毒核衣壳蛋白的抗原表位及其用途 |
| EP3418300B1 (en) | 2011-07-18 | 2020-10-28 | Institute for Research in Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| JP2013087069A (ja) * | 2011-10-17 | 2013-05-13 | Toyobo Co Ltd | Ｈ５亜型インフルエンザウイルスを特異的に認識するモノクローナル抗体 |
| JP6371222B2 (ja) | 2011-12-05 | 2018-08-08 | トレリス バイオサイエンス リミテッド ライアビリティー カンパニー | インフルエンザの受動免疫用抗体 |
| SG11201403773WA (en) | 2012-01-12 | 2014-07-30 | Temasek Life Sciences Lab Ltd | Monoclonal antibodies targeting neutralizing epitopes on h5 influenza virus of clade 2.3 |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| SG11201503734UA (en) | 2012-11-13 | 2015-06-29 | Genentech Inc | Anti-hemagglutinin antibodies and methods of use |
| EP3003373A4 (en) | 2013-03-14 | 2016-10-19 | Contrafect Corp | COMPOSITION AND METHODS BASED ON INTRANASALLY RELEASED NEUTRALIZING ANTIBODIES FOR IMPROVED THERAPEUTIC EFFECTIVENESS |
| SG10202103140XA (en) | 2013-10-02 | 2021-05-28 | Medimmune Llc | Neutralizing anti-influenza a antibodies and uses thereof |
| RU2720282C1 (ru) | 2014-02-04 | 2020-04-28 | Контрафект Корпорейшн | Антитела, подходящие для пассивной иммунизации против гриппа, и их композиции, комбинации и способы применения |
| US10639370B2 (en) | 2014-02-04 | 2020-05-05 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
| KR101628331B1 (ko) * | 2014-03-28 | 2016-06-08 | 주식회사 녹십자엠에스 | 인플루엔자 a 바이러스 특이적 단클론 항체 및 이를 이용한 인플루엔자 감염 치료 및 진단 방법 |
| JP6614523B2 (ja) * | 2014-03-28 | 2019-12-04 | 地方独立行政法人神奈川県立産業技術総合研究所 | インフルエンザウイルスのｒｎａ依存性ｒｎａポリメラーゼのｐｂ２サブユニットに対するモノクローナル抗体 |
| RU2739952C2 (ru) | 2014-07-15 | 2020-12-30 | МЕДИММЬЮН, ЭлЭлСи | Нейтрализующие антитела к вирусу гриппа b и пути их применения |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| CN108135994B (zh) | 2015-05-13 | 2022-01-25 | 宾夕法尼亚州大学信托人 | Aav-介导的抗-流感抗体的表达及其使用方法 |
| MX389708B (es) | 2015-06-01 | 2025-03-20 | Medimmune Llc | Neutralizacion de moleculas de union anti-influenza y usos de las mismas. |
| WO2017083627A1 (en) | 2015-11-13 | 2017-05-18 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| SG11201805001UA (en) | 2016-01-13 | 2018-07-30 | Medimmune Llc | Method of treating influenza a |
| WO2017147248A1 (en) | 2016-02-24 | 2017-08-31 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
| PL238020B1 (pl) * | 2016-09-12 | 2021-06-28 | Inst Biotechnologii I Antybiotykow | Kompozycja przeciwciał monoklonalnych przeciwko hemaglutyninie wirusów grypy serotypu H5 i jej zastosowanie, hybrydomy produkujące rzeczone przeciwciała, sposób diagnozowania infekcji wirusami grypy serotypu H5 oraz zestawy diagnostyczne |
| SG11201907611WA (en) | 2017-02-28 | 2019-09-27 | Univ Pennsylvania | Influenza vaccines based on aav vectors |
| US11827906B2 (en) | 2017-02-28 | 2023-11-28 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) clade f vector and uses therefor |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| EP3630841A1 (en) | 2017-06-02 | 2020-04-08 | Pfizer Inc. | Antibodies specific for flt3 and their uses |
| CN113924147A (zh) | 2019-03-25 | 2022-01-11 | 威特拉公司 | 用于治疗和预防流感的组合物和方法 |
| US20240288426A1 (en) * | 2020-01-12 | 2024-08-29 | Vanderbilt University | Human antibodies to crimean congo hemorrhagic fever virus |
| WO2021202815A1 (en) * | 2020-03-31 | 2021-10-07 | Northeastern University | Colorimetric and multiplexed isothermal rna-and antibody-based assay for sars-cov-2 and other viral diagnostics and cell analysis |
| CN114181302B (zh) * | 2020-09-14 | 2023-03-24 | 东莞市朋志生物科技有限公司 | 针对甲型流感病毒的抗体、试剂盒和载体 |
| US12319747B2 (en) | 2023-07-03 | 2025-06-03 | Medicovestor, Inc. | Methods of using anti-SP17 immunotherapeutics |
| US12364777B2 (en) | 2023-10-20 | 2025-07-22 | Medicovestor, Inc. | Homodimeric antibodies for use in treating cancers and methods of use |
| US12116410B1 (en) | 2023-12-26 | 2024-10-15 | Medicovestor, Inc. | Methods of manufacturing dimeric antibodies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2817869B1 (fr) | 2000-12-07 | 2005-01-14 | Technopharm | Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci |
| WO2003078600A2 (en) * | 2002-03-13 | 2003-09-25 | Kirin Beer Kabushiki Kaisha | Human monoclonal antibodies to influenza m2 protein and methods of making and using same |
| WO2007021002A1 (ja) | 2005-08-19 | 2007-02-22 | Bl Co., Ltd. | インフルエンザウイルスｈ５亜型の免疫検出法 |
| US8642513B2 (en) | 2005-09-15 | 2014-02-04 | Crucell Holland B.V. | Method for preparing immunoglobulin libraries |
| GB0522460D0 (en) | 2005-11-03 | 2005-12-14 | Prendergast Patrick T | Composition and method for the treatment of avian influenza |
| CA2637837A1 (en) * | 2006-01-26 | 2007-08-09 | Hx Diagnostics, Inc. | Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof |
| WO2007134327A2 (en) * | 2006-05-15 | 2007-11-22 | Sea Lane Biotechnologies, Llc. | Neutralizing antibodies to influenza viruses |
| MY170607A (en) * | 2006-09-07 | 2019-08-20 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| CN101541832B (zh) * | 2006-09-07 | 2014-11-12 | 克鲁塞尔荷兰公司 | 能中和流感病毒h5n1的人结合分子及其应用 |
| WO2008033105A1 (en) | 2006-09-13 | 2008-03-20 | Dso National Laboratories | Hemagglutinin antibody and uses thereof |
| EP2061808A4 (en) | 2006-09-15 | 2009-11-18 | Fraunhofer Usa Inc | INFLUENZA ANTIBODIES, COMPOSITIONS AND RELATED METHODS |
| JP5346820B2 (ja) * | 2007-03-13 | 2013-11-20 | エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー | Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体 |
-
2008
- 2008-03-13 JP JP2009553239A patent/JP5346820B2/ja not_active Expired - Fee Related
- 2008-03-13 CN CN2008800130493A patent/CN102046654A/zh active Pending
- 2008-03-13 EP EP08762860A patent/EP2125886A2/en not_active Withdrawn
- 2008-03-13 US US12/048,040 patent/US8124092B2/en not_active Expired - Fee Related
- 2008-03-13 WO PCT/IB2008/001527 patent/WO2008110937A2/en not_active Ceased
-
2012
- 2012-01-16 US US13/351,066 patent/US20120114664A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2125886A2 (en) | 2009-12-02 |
| WO2008110937A2 (en) | 2008-09-18 |
| US20100278834A1 (en) | 2010-11-04 |
| US20120114664A1 (en) | 2012-05-10 |
| US8124092B2 (en) | 2012-02-28 |
| CN102046654A (zh) | 2011-05-04 |
| WO2008110937A3 (en) | 2009-04-30 |
| JP2010521147A (ja) | 2010-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5346820B2 (ja) | Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体 | |
| JP6022515B2 (ja) | 抗ａ型インフルエンザウイルス中和抗体およびその使用 | |
| JP6035332B2 (ja) | Ａ型インフルエンザウイルス中和抗体及びその使用法 | |
| JP5814790B2 (ja) | デングウイルス中和抗体およびその使用 | |
| KR102555955B1 (ko) | 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법 | |
| CN104892753B (zh) | 一种中和人感染h7n9甲型流感病毒的抗体及其用途 | |
| US10654915B2 (en) | Antibodies useful in passive influenza immunization | |
| WO2016109774A1 (en) | Bispecific antibodies against plasma kallikrein and factor xii | |
| CN113480640B (zh) | 中和抗流感结合分子及其用途 | |
| WO2008125985A2 (en) | Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes | |
| US20240092875A1 (en) | Sars-cov-2 antibodies for treatment and prevention of covid-19 | |
| JP6101204B2 (ja) | インフルエンザｈ５赤血球凝集素の主要中和エピトープに特異的なモノクローナル抗体 | |
| US20100061995A1 (en) | Immunotherapy To Treat Or Prevent Viral Infection | |
| JP2024536380A (ja) | 抗ＳＡＲＳ－ＣｏＶ－２抗体及びその使用Ｉ | |
| JP6622825B2 (ja) | Ａ型インフルエンザウイルス中和抗体及びその使用法 | |
| US20220340644A1 (en) | Influenza neutralizing antibodies and their uses | |
| JP2017086068A (ja) | Ａ型インフルエンザウイルス中和抗体及びその使用法 | |
| HK1260890B (zh) | 登革热病毒中和抗体及其用途 | |
| HK1203410B (en) | Antibodies useful in passive influenza immunization | |
| HK1164898B (en) | Dengue virus neutralizing antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110311 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110311 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130319 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130619 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130626 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130703 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130730 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130819 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |